Study of Eculizumab in Adult Subjects at Risk for Developing Delayed Graft Function.

Registry ID

EUCTR2013-004650-25

Source registry

EUCTR

Status

Completed

Phase

PHASE3

Sponsor

Alexion Pharmaceuticals Incorporated

Start date

2014-06-25

Completion date

2016-11-22

Last update

2026-08-16

Conditions

• Delayed Graft Function

Summary

Efficacy and safety of eculizumab to prevent DGF in adult diseased donor kidney transplants recipients at increased risk of DGF.

Locations

• , , Czechia
• , , France
• , , Italy
• , , Germany
• , , Spain

Related clinical trials

• Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
• Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During Kidney Transplantation
• The Effects of Vonoprazan Fumarate on DGF Incidence in DD Kidney Transplant Recipients

View on source registry